Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Edwards Lifesciences (EW) director reports a small stock sale. A company director filed to disclose the sale of 2,615 shares of Edwards Lifesciences common stock on 12/12/2025 at a price of $83.4109 per share, coded as an open market sale (transaction code "S").
After this transaction, the reporting person beneficially owns 30,948 shares of Edwards Lifesciences common stock in direct form. The filing is made by a single reporting person and expressly notes that it reflects only the change in beneficial ownership reported here and does not list all other securities of the company that the insider may own.
EW filed a Rule 144 notice covering a proposed sale of 5,900 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $494,066.00. The notice states that there were 580,300,000 common shares outstanding at the time of the filing. The shares to be sold were originally acquired from the issuer between December 12, 2021 and May 8, 2022 through restricted stock vesting and option exercises under registered equity plans, all paid for in cash. The seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Edwards Lifesciences (EW) insider plans modest Rule 144 sale of common stock. A holder intends to sell 2,615 shares of Edwards Lifesciences common stock through broker Charles Schwab & Co., Inc. on the NYSE, with an aggregate market value of $218,119.00. The filing notes that approximately 580,300,000 shares of common stock were outstanding, providing context for the small size of this planned sale. The shares to be sold were acquired on 05/03/2022 through a restricted stock lapse as equity compensation from Edwards Lifesciences Corporation.
Edwards Lifesciences executive plans modest stock sale under Rule 144. A notice was filed for the proposed sale of 5,487 shares of Edwards Lifesciences common stock through broker Charles Schwab & Co., Inc. on or about 12/12/2025 on the NYSE. The shares have an aggregate market value of $459,682.00 based on the price used in the notice, compared with 580,300,000 Edwards Lifesciences shares stated as outstanding.
The seller acquired these 5,487 shares on 05/08/2023 as equity compensation via RSU/PSU awards from Edwards Lifesciences Corporation. The filing also reports that, over the prior three months, the same individual sold 11,340 Edwards Lifesciences shares on 12/10/2025 for gross proceeds of $950,582.00. The signer confirms they are not aware of undisclosed material adverse information about the company’s operations.
Edwards Lifesciences Corp
On 12/11/2025, the officer sold 2,000 shares of Edwards Lifesciences common stock at a price of $84.3751 per share. After this transaction, the officer beneficially owned 32,201 shares of the company’s common stock in direct ownership. The filing notes that it reflects changes in beneficial ownership only and does not list all securities of the issuer that may be beneficially owned by the reporting person.
A security holder of Edwards Lifesciences plans to sell 2,000 shares of the company’s common stock under Rule 144. The planned sale has an aggregate market value of $168,750 and is scheduled around December 11, 2025 through broker Charles Schwab & Co., Inc. on the NYSE. The filing notes that 580,300,000 shares of Edwards Lifesciences common stock were outstanding.
The shares to be sold come from prior equity compensation awards from Edwards Lifesciences. These include restricted stock that lapsed on May 3, 2023 and May 4, 2023 in amounts of 359 and 527 shares, and RSU/PSU awards acquired on May 7, 2023 totaling 1,114 shares. The seller represents that they are not aware of any undisclosed material adverse information about the company’s current or prospective operations.
Edwards Lifesciences Corp (EW) officer trades company stock through option exercise and sale. On 12/10/2025, the reporting person, a corporate vice president for strategy and corporate development, exercised an employee stock option for 11,340 shares of common stock at an exercise price of $59.2567 per share, then sold the same 11,340 shares at a weighted average price of $83.8255 per share in open-market transactions. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2025. After the transactions, the insider directly held 50,356.3707 shares, plus 38,817.6991 shares through a 401(k), 135,152 shares held by a trust, and 45,360 employee stock options.
Edwards Lifesciences CEO and director reported several equity transactions in company stock. On December 8, 2025, the insider exercised an employee stock option for 25,350 shares of common stock at an exercise price of $59.2567 per share, then sold 21,487 shares at a weighted average price of $85.2146. The option had been granted in 2019 under the company’s long-term stock incentive program.
On December 9, 2025, the insider transferred 3,863 shares from direct ownership and the same amount was recorded as held indirectly in a trust. On December 10, 2025, the trust sold 3,863 shares at $83.45 per share. After these transactions, the filing shows remaining direct and indirect holdings, including shares held through a trust and a 401(k). All reported trades were made under a Rule 10b5-1 trading plan adopted on February 28, 2025.
Edwards Lifesciences insider plans Rule 144 stock sale. A holder of Edwards Lifesciences common stock filed a notice to sell 11,340 shares through broker Charles Schwab & Co., Inc. on the NYSE, with an aggregate market value of $950,582. The filing shows 580,300,000 common shares outstanding for the issuer. The shares to be sold were acquired on 12/10/2025 through an employee stock option exercise, using a broker-facilitated cashless exercise structure.
Edwards Lifesciences has a shareholder filing a Form 144 notice to sell up to 3,863 common shares through Charles Schwab on or about December 10, 2025, with an aggregate market value of $322,367. The shares to be sold were acquired on December 8, 2025 via a restricted stock lapse as equity compensation from Edwards Lifesciences Corporation.
During the prior three months, the same seller disposed of 21,487 Edwards Lifesciences shares on December 8, 2025 for gross proceeds of $1,831,006. Edwards Lifesciences had 580,300,000 shares outstanding, providing context for the relative size of these planned and recent sales.